Novartis reported CHF4.77B in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alcon AG ALC:SW 500M 155M
Amgen AMGN:US $ 3188M 218M
AstraZeneca AZN:LN 2149M 322M
Bayer BAYN:GR € 3035M 1119M
Biogen BIIB:US $ 991.8M 155.8M
Bristol Myers Squibb BMY:US $ 5679M 455M
Eli Lilly And LLY:US $ 1797.7M 218.8M
Fresenius FRE:GR € 1684M 48M
Fresenius Medical Care FME:GR € 798M 36M
Galapagos GLPG:NA € -30.77M 15.01M
Gilead Sciences GILD:US $ 2816M 669M
GlaxoSmithKline GSK:LN 2626M 584M
GRIFOLS GRF:SM € 330.18M 44.07M
H. Lundbeck A/S LUN:DC 995M 357M
Hikma Pharmaceutical HIK:LN 358M 9M
Johnson & Johnson JNJ:US $ 8192M 2043M
Lonza Group LONN:SW 847M 291M
Merck MRK:GR € 1576M 61M
Novartis NOVN:VX SF 4772M 423M
Orion ORNBV:FH € 68.4M 13.6M
Pfizer PFE:US $ 7593M 610M
Philips PHIA:NA € 783M 202M
Recordati REC:IM € 150.19M 0.17M
Regeneron Pharmaceuticals REGN:US $ 3418.3M 2238.2M